Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the...
Pharmaceutical
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered...
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growthPALO ALTO, Calif., April...
AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants
Al Zeyoudi: "Hosting such major international events reflects the UAE's pivotal role as a global hub for investment and trade"1,250 speakers...
Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada
Burlington, Ontario--(Newsfile Corp. - April 3, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian...
FLO Living Partners with Leading Femtech Innovators to Conduct Study on the Cycle Syncing® Method
First-of-its-Kind Research Aims to Fill the Gap in Women's Hormonal Health NEW YORK, April 3, 2025 /PRNewswire/ -- FLO Living...
NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION
TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial...
WCG Announces Research Resilience Solutions to Navigate Institutional Budget Constraints
CARY, N.C., April 3, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical...
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO)...
Startup ProFuse Launches Pioneering Drug Discovery Platform for the Prevention of Muscle Loss
YOKNEAM ILLIT, Israel, April 3, 2025 /PRNewswire/ -- Israeli startup ProFuse Technology, which specializes in the cultivation of muscle tissue in laboratory...
Lindus Health Awarded Funding from ARIA to Build Safe and Reliable AI for Clinical Trial Design
BOSTON, April 3, 2025 /PRNewswire/ -- Lindus Health, the anti-CRO running radically faster, more reliable trials, has been awarded funding...
Natural selection for greener cleaning products?
An INRS study based on natural selection is paving the way for very promising advances in biosurfactants. LAVAL, QC, April 3,...
Vantive Chief Strategy Officer Joins Labviva Board
Esteemed Life Sciences Leader Joins Board to Enhance Strategic Direction During Company Expansion Ben Daverman, Vantive Chief Strategy Officer Joins...
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on...
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned...
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing...
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to...
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...